Get the Stockscreener App
14.07
0.07%
-0.010
Seres Therapeutics Inc stock is traded at $14.07, with a volume of 85,694.
It is down -0.07% in the last 24 hours and up +82.02% over the past month.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
See More
Previous Close:
$14.08
Open:
$14.56
24h Volume:
85,694
Relative Volume:
0.69
Market Cap:
$122.87M
Revenue:
$123.24M
Net Income/Loss:
$136.00K
P/E Ratio:
-703.50
EPS:
-0.02
Net Cash Flow:
$-148.99M
1W Performance:
+11.93%
1M Performance:
+82.02%
6M Performance:
-8.33%
1Y Performance:
-44.17%
1-Day Range:
$14.04
$14.78
1-Week Range:
$12.08
$15.98
52-Week Range:
$6.53
$29.40
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617 945 9626
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
14.07 | 109.77M | 123.24M | 136.00K | -148.99M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-08-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-24-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-21-23 | Initiated | JP Morgan | Neutral |
| Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
| May-18-21 | Resumed | Goldman | Neutral |
| Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
| Apr-30-19 | Initiated | Jefferies | Hold |
| Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-17 | Initiated | Oppenheimer | Outperform |
| Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-01-17 | Reiterated | FBR & Co. | Outperform |
| Aug-12-16 | Reiterated | FBR Capital | Outperform |
| Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
| Jul-29-16 | Resumed | H.C. Wainwright | Buy |
| Mar-30-16 | Initiated | FBR Capital | Outperform |
| Mar-03-16 | Initiated | Guggenheim | Buy |
| Jan-25-16 | Initiated | H.C. Wainwright | Buy |
| Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-22-15 | Initiated | Canaccord Genuity | Buy |
| Jul-21-15 | Initiated | Goldman | Neutral |
| Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
Seres Therapeutics Inc. Stock Analysis and ForecastMarket-beating performance - Jammu Links News
Is Seres Therapeutics Inc. a good long term investmentExplosive earnings growth - Jammu Links News
what makes seres therapeutics inc. stock price move sharplyChart Breakout Alert - Newser
How high can Seres Therapeutics Inc. stock price go in 2025Protected Capital Trading Plan - Newser
What analysts say about Seres Therapeutics Inc. stockLightning-fast growth - Jammu Links News
What makes Seres Therapeutics Inc. stock price move sharplyFree Trading Group - Newser
Why Seres Therapeutics Inc. stock attracts strong analyst attentionFree Smart Money Group - Newser
How Seres Therapeutics Inc. stock performs during market volatilityInsider Strategy Insight - Newser
Seres Therapeutics Soars 21%—What’s Fueling the Biotech Breakout? - AInvest
5 Best Microbiome Companies (July 2025) - Securities.io
Seres Therapeutics, Inc.(NasdaqGS: MCRB) added to Russell 3000E Index - MarketScreener
Seres Therapeutics, Inc.(NasdaqGS: MCRB) added to Russell Microcap Growth Index - MarketScreener
Seres Therapeutics May 2025 slides: SER-155 shows 77% infection reduction in transplant patients - Investing.com
FMR LLC Reduces Stake in Seres Therapeutics Inc: A Strategic Rea - GuruFocus
Denodo University Challenge Now Open: Data and AI for Real-World Impact - GlobeNewswire Inc.
Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of “Reduce” by Brokerages - Defense World
Seres Therapeutics reports promising biomarker data By Investing.com - Investing.com South Africa
Seres Therapeutics (MCRB) to Present New Biomarker Data at ASCO 2025 | MCRB Stock News - GuruFocus
Seres Therapeutics reports promising biomarker data - Investing.com
Seres Therapeutics to Present New Biomarker Data from SER-155 Phase 1b Study at 2025 ASCO Annual Meeting - Nasdaq
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting - The Manila Times
Breakthrough: Seres Therapy Cuts Deadly Infection Risk by 77% in Cancer Transplant Patients, ASCO Data Shows - Stock Titan
Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below Two Hundred Day Moving Average – Here’s Why - Defense World
Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade - NewsBreak: Local News & Alerts
Human Microbiome Market Forecast: Growth Trends, Key Players & - openPR.com
Seres Therapeutics’ (MCRB) “Neutral” Rating Reiterated at Chardan Capital - Defense World
StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold - Defense World
Seres Therapeutics Shares Fall After Downgrade From Chardan - marketscreener.com
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript - Insider Monkey
This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
Chardan Downgrades Seres Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $25 - marketscreener.com
MCRB: Seres Therapeutics' Price Target Raised by Chardan Capital | MCRB Stock News - GuruFocus
Chardan cuts Seres Therapeutics stock rating to neutral - Investing.com
Seres Therapeutics: Q1 Earnings Snapshot - Norwalk Hour
Seres Therapeutics Reports Positive Q1 2025 Results - TipRanks
Seres Therapeutics’ Positive Earnings Call: Progress and Challenges - TipRanks
Transcript : Seres Therapeutics, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
Earnings call transcript: Seres Therapeutics Q1 2025 sees net income boost - Investing.com Nigeria
Seres Therapeutics, Inc. SEC 10-Q Report - TradingView
Seres Therapeutics Advances SER-155 Program with FDA Submission - TipRanks
Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Seres Therapeutics (MCRB) Targets Advancement of SER-155 in Clinical Development | MCRB Stock News - GuruFocus
Seres Therapeutics Inc Stock (MCRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Seres Therapeutics Inc Stock (MCRB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shaff Eric D. | CEO and President |
May 16 '25 |
Sale |
7.28 |
220 |
1,602 |
10,102 |
| DesRosier Thomas | Chief Legal Officer and EVP |
May 15 '25 |
Sale |
7.28 |
79 |
575 |
7,287 |
| Henn Matthew R | See Remarks |
May 16 '25 |
Sale |
7.28 |
77 |
561 |
4,383 |
| Young Teresa L. | See Remarks |
Feb 18 '25 |
Sale |
0.81 |
3,338 |
2,704 |
97,536 |
| Henn Matthew R. | See Remarks |
Feb 18 '25 |
Sale |
0.81 |
3,953 |
3,204 |
84,443 |
| Shaff Eric D. | CEO and President |
Feb 18 '25 |
Sale |
0.81 |
12,726 |
10,314 |
192,039 |
| DesRosier Thomas | Chief Legal Officer and EVP |
Feb 18 '25 |
Sale |
0.81 |
4,300 |
3,485 |
142,456 |
| von Moltke Lisa | See Remarks |
Feb 18 '25 |
Sale |
0.81 |
4,416 |
3,579 |
39,875 |
| DesRosier Thomas | Chief Legal Officer and EVP |
Nov 18 '24 |
Sale |
0.54 |
878 |
475 |
135,192 |
| von Moltke Lisa | See Remarks |
Nov 18 '24 |
Sale |
0.54 |
977 |
528 |
32,415 |
0.59%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):